Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.10.0.1
Earnings (Loss) Per Common Share (Tables)
 12 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
Years ended

‎
June 30,
 
 
 
2018
 
 
2017
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to iBio, Inc. stockholders
 
$
(16,105
)
 
$
(14,532
)
Preferred stock dividends
 
 
(260
)
 
 
(90
)
Net loss available to iBio, Inc. stockholders
 
$
(16,365
)
 
$
(14,622
)
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
10,631
 
 
 
8,911
 
 
 
 
 
 
 
 
 
 
Per share amount
 
$
(1.54
)
 
$
(1.64
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] As of June 30, 2018, shares issuable which could potentially dilute future earnings included were as follows.
 
 
 
Year Ended

‎
June 30,
 
 
 
2018
 
 
2017
 
 
 
(in thousands)
 
Stock options
 
 
1,365
 
 
 
1,355
 
Series A Preferred
 
 
6,900
 
 
 
-
 
Series B Preferred
 
 
6,428
 
 
 
-
 
Shares excluded from the calculation of diluted loss per share
 
 
14,693
 
 
 
1,355